CTD regimen: Difference between revisions
Created page with "__NOTOC__ [[{{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a regimen consisting of Cyclophosphamide, Thalidomide, Dexamethasone us..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{SI}} {{CMG}}; {{AE}} {{AV}} | |||
{{SK}} | {{SK}} | ||
| Line 7: | Line 7: | ||
{{PAGENAME}} refers to a regimen consisting of [[Cyclophosphamide]], [[Thalidomide]], [[Dexamethasone]] used to treat [[Multiple myeloma]] unsuitable | {{PAGENAME}} refers to a regimen consisting of [[Cyclophosphamide]], [[Thalidomide]], [[Dexamethasone]] used to treat [[Multiple myeloma]] unsuitable | ||
for autologous transplantation<ref name="pmid21652683">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ et al.| title=Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. | journal=Blood | year= 2011 | volume= 118 | issue= 5 | pages= 1231-8 | pmid=21652683 | doi=10.1182/blood-2011-02-338665 | pmc=PMC3152492 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21652683 }} </ref> | for autologous transplantation<ref name="pmid21652683">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ et al.| title=Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. | journal=Blood | year= 2011 | volume= 118 | issue= 5 | pages= 1231-8 | pmid=21652683 | doi=10.1182/blood-2011-02-338665 | pmc=PMC3152492 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21652683 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|C|Cyclophosphamide}} | {{chemo|C|Cyclophosphamide}} | ||
{{chemo|T|Thalidomide}} | {{chemo|T|Thalidomide}} | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
==Indications== | ==Indications== | ||
*[[Multiple myeloma]]<ref name="pmid21652683">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ et al.| title=Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. | journal=Blood | year= 2011 | volume= 118 | issue= 5 | pages= 1231-8 | pmid=21652683 | doi=10.1182/blood-2011-02-338665 | pmc=PMC3152492 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21652683 }} </ref> | *[[Multiple myeloma]]<ref name="pmid21652683">{{cite journal| author=Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ et al.| title=Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. | journal=Blood | year= 2011 | volume= 118 | issue= 5 | pages= 1231-8 | pmid=21652683 | doi=10.1182/blood-2011-02-338665 | pmc=PMC3152492 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21652683 }} </ref> | ||
Revision as of 13:59, 12 March 2015
|
WikiDoc Resources for CTD regimen |
|
Articles |
|---|
|
Most recent articles on CTD regimen Most cited articles on CTD regimen |
|
Media |
|
Powerpoint slides on CTD regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on CTD regimen at Clinical Trials.gov Clinical Trials on CTD regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on CTD regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on CTD regimen Discussion groups on CTD regimen Patient Handouts on CTD regimen Directions to Hospitals Treating CTD regimen Risk calculators and risk factors for CTD regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for CTD regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:
Overview
CTD regimen refers to a regimen consisting of Cyclophosphamide, Thalidomide, Dexamethasone used to treat Multiple myeloma unsuitable for autologous transplantation[1]
Regimen
CCyclophosphamide
TThalidomide
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ; et al. (2011). "Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation". Blood. 118 (5): 1231–8. doi:10.1182/blood-2011-02-338665. PMC 3152492. PMID 21652683.